Population distributions of phenylbutazone and oxyphenbutazone after oral and i.v. dosing in horses

Authors


Abstract

Experiments to determine the residual plasma concentrations of phenylbutazone and its metabolites found in horses racing on a ‘no-race day medication’ or 24-h rule were carried out. One dosing schedule (oral-i.v.) consisted of 8.8 mg/kg (4g/1000 lbs) orally for 3 days, followed by 4.4 mg/kg (2g/1000 lbs) intravenously on day 4. A second schedule consisted of 4.4 mg/kg i.v. for 4 days. The experiments were carried out in Thoroughbred and Standardbred horses at pasture, half-bred horses at pasture, and in Thoroughbred horses in training.

After administering the i.v. schedule for 4 days to Thoroughbred and Standard-bred horses at pasture, the mean plasma concentrations of phenylbutazone increased from 0.77 μg/ml on day 2 to 2.5 μg/ml on day 5. The shape of the frequency distribution of these populations was log-normal. These data are consistent with one horse in 1,000 yielding a plasma level of 8.07 μg/ml on day 5.

After administration of the oral-i.v. schedule to Thoroughbred and Standard-bred horses at pasture, the mean plasma concentrations of phenylbutazone were 3.4 μg/ml on day 2 and 3.5μg/ml on day 5. The range on day 5 was from 1.4 to 8.98 μg/ml and the frequency distribution was log-normal. These data are consistent with one horse in 1000 having a plasma level of 15.8 μg/ml on day 5.

In a final experiment, the oral dosing schedule was administered to 62 Thoroughbred horses in training. Plasma concentrations on day 5 in these horses averaged 5.3 μg/ml. The range was from 1.3 to 13.6 μg/ml and the frequency distribution was log-normal. Statistical projection of these values suggests that following this oral dosing schedule in racing horses about one horse in 1000 will yield a plasma level of 23.5 μg/ml of phenylbutazone 24h after the last dose.

Ancillary